UNLABELLED: Tumor uptake of copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (copper-ATSM), a hypoxia-targeting radiopharmaceutical, assessed by PET has been found to correlate with prognosis in several human cancers. Wide clinical utility of this tracer will require its labeling with a copper radionuclide having a longer half-life than the (60)Cu used in studies to date. The purpose of this work was to obtain the requisite preclinical data for copper-ATSM to file an investigational new drug application, followed by a crossover comparison of PET image quality and tumor uptake with (60)Cu-ATSM and (64)Cu-ATSM in women with cancer of the uterine cervix. METHODS: The preclinical toxicology and pharmacology of a copper-ATSM formulation was examined using standard in vitro and in vivo assays, as well as 14-d toxicity studies in both rats and rabbits. For the clinical test-retest imaging study, 10 patients with cervical carcinoma underwent PET on separate days with (60)Cu-ATSM and (64)Cu-ATSM. Image quality was assessed qualitatively, and the tumor-to-muscle activity ratio was measured for each tracer. RESULTS: The toxicology and pharmacology data demonstrated that the formulation has an appropriate margin of safety for clinical use. In the patient study, we found that the image quality with (64)Cu-ATSM was better than that with (60)Cu-ATSM because of lower noise. In addition, we found that the pattern and magnitude of tumor uptake of (60)Cu-ATSM and (64)Cu-ATSM on studies separated by 1-9 d were similar. CONCLUSION: (64)Cu-ATSM appears to be a safe radiopharmaceutical that can be used to obtain high-quality images of tumor hypoxia in human cancers.
UNLABELLED: Tumor uptake of copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (copper-ATSM), a hypoxia-targeting radiopharmaceutical, assessed by PET has been found to correlate with prognosis in several humancancers. Wide clinical utility of this tracer will require its labeling with a copper radionuclide having a longer half-life than the (60)Cu used in studies to date. The purpose of this work was to obtain the requisite preclinical data for copper-ATSM to file an investigational new drug application, followed by a crossover comparison of PET image quality and tumor uptake with (60)Cu-ATSM and (64)Cu-ATSM in women with cancer of the uterine cervix. METHODS: The preclinical toxicology and pharmacology of a copper-ATSM formulation was examined using standard in vitro and in vivo assays, as well as 14-dtoxicity studies in both rats and rabbits. For the clinical test-retest imaging study, 10 patients with cervical carcinoma underwent PET on separate days with (60)Cu-ATSM and (64)Cu-ATSM. Image quality was assessed qualitatively, and the tumor-to-muscle activity ratio was measured for each tracer. RESULTS: The toxicology and pharmacology data demonstrated that the formulation has an appropriate margin of safety for clinical use. In the patient study, we found that the image quality with (64)Cu-ATSM was better than that with (60)Cu-ATSM because of lower noise. In addition, we found that the pattern and magnitude of tumor uptake of (60)Cu-ATSM and (64)Cu-ATSM on studies separated by 1-9 d were similar. CONCLUSION: (64)Cu-ATSM appears to be a safe radiopharmaceutical that can be used to obtain high-quality images of tumor hypoxia in humancancers.
Authors: Jason D Wright; Farrokh Dehdashti; Thomas J Herzog; David G Mutch; Phyllis C Huettner; Janet S Rader; Randall K Gibb; Matthew A Powell; Feng Gao; Barry A Siegel; Perry W Grigsby Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: D W McCarthy; R E Shefer; R E Klinkowstein; L A Bass; W H Margeneau; C S Cutler; C J Anderson; M J Welch Journal: Nucl Med Biol Date: 1997-01 Impact factor: 2.408
Authors: Farrokh Dehdashti; Mark A Mintun; Jason S Lewis; Jeffrey Bradley; Ramaswamy Govindan; Richard Laforest; Michael J Welch; Barry A Siegel Journal: Eur J Nucl Med Mol Imaging Date: 2003-04-12 Impact factor: 9.236
Authors: Farrokh Dehdashti; Perry W Grigsby; Jason S Lewis; Richard Laforest; Barry A Siegel; Michael J Welch Journal: J Nucl Med Date: 2008-01-16 Impact factor: 10.057
Authors: Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis Journal: Dalton Trans Date: 2019-10-07 Impact factor: 4.390
Authors: Mathew L Thakur; Kaijun Zhang; Adam Berger; Barbara Cavanaugh; Sung Kim; Chaitra Channappa; Andrea J Frangos; Eric Wickstrom; Charles M Intenzo Journal: J Nucl Med Date: 2013-05-07 Impact factor: 10.057